Mark A. Goldsmith, M.D., Ph.D., is a distinguished leader in the field of oncology and drug development, currently serving as the President and Chief Executive Officer of Revolution Medicines, Inc. Dr. Goldsmith's career is marked by his profound expertise in molecular and cellular biology, as well as his commitment to advancing cancer treatment. He holds both an M.D. and a Ph.D. from the University of California, San Francisco, where he also completed his residency in internal medicine and fellowship in oncology. His academic journey laid a strong foundation for his subsequent contributions to the biotechnology industry. Before joining Revolution Medicines, Dr. Goldsmith held significant leadership roles that shaped his approach to drug discovery and development. He was the Senior Vice President of Research and Development at Elan Pharmaceuticals, where he played a pivotal role in advancing the company's pipeline in neurodegenerative diseases. Additionally, he co-founded and served as CEO of OncoMed Pharmaceuticals, a company focused on developing novel cancer therapeutics. His tenure at OncoMed was marked by the successful progression of several drug candidates into clinical trials, demonstrating his ability to translate scientific insights into tangible medical advancements. At Revolution Medicines, Dr. Goldsmith leads the company's efforts to develop targeted therapies that address the genetic drivers of cancer. Under his stewardship, the company is pursuing innovative approaches to inhibit RAS and other oncogenic mutations, aiming to transform the treatment landscape for patients with cancer.